Short answer
Praxis Precision Medicines, Inc. (PRAX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$84M
- −17.7% YoY · +9.6% QoQ
- EPS (diluted)
- −$2.88
- +13.0% YoY · +10.0% QoQ
Source: XBRL data from the Praxis Precision Medicines, Inc. (PRAX) Q2 2026 10-Q on SEC EDGAR. USD.
Praxis Precision Medicines, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY; no product sales since inception
- Net loss $83.7M vs $71.1M YoY; operating loss $96.9M vs $76.1M
- Solidus R&D $8.7M vs $2.0M; Cerebrum R&D $40.4M vs $47.0M
- Cash, equivalents and marketable securities $1.4B at June 30, 2026; funding expected into 2028
- Near-term catalysts: relutrigine PDUFA December 27, 2026; ulixacaltamide PDUFA January 29, 2027; vormatrigine POWER1 endpoint failure headwind
Risk Factors
- No material changes to 10-K risk factors for year ended December 31, 2025
- Regulatory and compliance risks carried forward from February 19, 2026 10-K
- Operational and competitive risks unchanged from 2025 Annual Report
- Financial and liquidity risks unchanged from 2025 Annual Report
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Praxis Precision Medicines, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.